Need Insurance Coverage?
Learn how to get Foundayo covered by insurance — step-by-step guide to prior authorization, appeals (65%+ success rate), and self-pay options.
Overview
What Is Foundayo?
Foundayo (orforglipron) is the first non-peptide oral GLP-1 receptor agonist approved for chronic weight management. FDA-approved on April 1, 2026, it's manufactured by Eli Lilly—the same company behind Zepbound and Mounjaro.[1]
Foundayo At a Glance
- Brand Name: Foundayo
- Generic Name: Orforglipron
- Manufacturer: Eli Lilly
- Drug Class: Non-peptide oral GLP-1 receptor agonist
- Administration: Once-daily pill (any time of day)
- Available Doses: 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, 17.2mg
- FDA Approval: April 1, 2026
- Indication: Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity
Key Differentiator: No Food Restrictions
Unlike oral Wegovy (which requires 30-minute fasting before eating), Foundayo can be taken any time of day with or without food. No water restrictions, no waiting—just take it when it's convenient for you.[1]
Availability
Is Foundayo Available? Where Can I Get It?
Yes—Foundayo is available now. The FDA approved Foundayo on April 1, 2026, and Eli Lilly began shipping through LillyDirect on April 6, 2026.[1]
How to Get Foundayo
- Get a prescription from your doctor or through a telehealth provider
- Choose your access path:
- LillyDirect — $149–$299/month, ships to your door
- Insurance — Coverage varies, may require prior authorization
- Savings Card — as little as $25/month with commercial insurance
- If denied coverage, we can help you appeal (65%+ success rate)
Mechanism
How Does Foundayo Work?
Foundayo is a GLP-1 receptor agonist—it mimics a natural hormone (GLP-1) that regulates appetite and blood sugar. When you take Foundayo, it activates GLP-1 receptors in your body, leading to:[2]
- Reduced appetite: You feel full sooner and stay satisfied longer
- Slower gastric emptying: Food moves through your stomach more slowly
- Better blood sugar control: Improved insulin response when blood sugar is elevated
- Reduced cravings: Less drive to eat between meals
What Makes Foundayo Different?
Foundayo is a non-peptide (small molecule) GLP-1 agonist. Unlike peptide-based oral GLP-1s (like Rybelsus or oral Wegovy), its molecular structure allows it to be absorbed reliably without food restrictions.[2]
Important: Foundayo targets only GLP-1 receptors. It is NOT a dual GIP/GLP-1 agonist like Zepbound (tirzepatide). This means somewhat lower weight loss (~12% vs ~20–22%) but in a more convenient oral format.
Foundayo Dosing
Foundayo is available in six doses for gradual titration. Your doctor will start you at the lowest dose and increase as tolerated.
| Dose | LillyDirect Price | Notes |
|---|---|---|
| 0.8mg | $149/month | Starting dose |
| 2.5mg | $149/month* | Titration |
| 5.5mg | $199/month* | Titration |
| 9mg | $299/month | Titration |
| 14.5mg | $299/month** | Maintenance |
| 17.2mg | $299/month** | Highest dose (max efficacy) |
*2.5mg and 5.5mg prices are temporarily reduced through December 31, 2026. **14.5mg and 17.2mg stay at $299 only when refilled within 45 days; otherwise $349/month. Pricing subject to change.[7]
Clinical Evidence
How Effective Is Foundayo for Weight Loss?
Foundayo was studied in the ATTAIN clinical trial program—over 4,500 participants across multiple Phase 3 studies. Results were published in the New England Journal of Medicine.[3]
ATTAIN-1 Results: Adults with Obesity (Without Diabetes)
Source: ATTAIN-1 Trial (NCT05869903), 72 weeks[3]
Weight Loss by Dose (ATTAIN-1 Trial Doses)
Trial used investigational doses. Commercial formulation uses different dose strengths with similar efficacy expected.
| Trial Dose | Avg Weight Loss | ≥5% Responders | ≥15% Responders |
|---|---|---|---|
| Low (6mg) | 7.8% | 63.8% | 16.5% |
| Mid (12mg) | 9.3% | 69.3% | 24.0% |
| High (36mg) | 12.4% | 77.1% | 39.6% |
| Placebo | 2% | 22.1% | 3.6% |
ATTAIN-2: Results in Type 2 Diabetes
In adults with obesity AND type 2 diabetes (ATTAIN-2 trial):[4]
- Highest trial dose: 9.6% average weight loss
- A1C reduction: 1.9% at highest dose
- Significant improvements in blood pressure and lipids
Weight loss is typically lower in patients with diabetes, which is consistent across all GLP-1 medications.
Bottom Line
Foundayo delivers about 12% weight loss—one of the first daily pills to achieve double-digit weight loss. While injectable options like Zepbound (~20–22%) and Wegovy (~15%) produce more weight loss, Foundayo offers meaningful results with the convenience of a pill you can take any time.[3]
Comparison
Foundayo vs Zepbound vs Wegovy
How does Foundayo stack up against other GLP-1 medications? Here's a side-by-side comparison:
*Oral Wegovy ~15% is an approximation; actual trial results range from 13.6% (treatment-regimen estimand) to 16.6% (efficacy estimand).
| Feature | Foundayo | Zepbound | Wegovy |
|---|---|---|---|
| Administration | Daily pill | Weekly injection | Weekly injection |
| Mechanism | GLP-1 only | Dual GIP/GLP-1 | GLP-1 only |
| Weight Loss | ~12% | ~20–22% | ~15% |
| Monthly Cost (Self-Pay) | $149–$299 | $299–$449 | $349 |
| Food Restrictions | None | N/A (injection) | N/A (injection) |
| Refrigeration | No | Yes | Yes |
| Manufacturer | Eli Lilly | Eli Lilly | Novo Nordisk |
Who Should Consider Foundayo?
- Needle-averse patients — No injections required
- Busy schedules — Take any time, no fasting requirements
- Frequent travelers — No refrigeration, easy to pack
- Cost-conscious — $149–$299/month vs $1,000+ for injectables
- Convenience priority — Willing to accept ~12% weight loss for daily pill format
Who Might Prefer Injectables?
- Maximum efficacy seekers — Zepbound delivers ~20–22% weight loss
- Once-weekly preference — Some prefer weekly dosing over daily
- Dual mechanism benefits — Zepbound's GIP/GLP-1 action may help some patients more
Switching from Another GLP-1?
If you're currently on Zepbound, Wegovy, or another GLP-1, here's what you need to know:
- Don't take concurrently: Foundayo's prescribing information warns against using other GLP-1 receptor agonists at the same time
- No formal washout: Your doctor will advise on timing, but there's typically no required "washout period"—you'll simply stop one and start the other
- Expect re-titration: You'll start at the lowest Foundayo dose (0.8mg) regardless of your previous GLP-1 dose
- Side effects may return: GI symptoms often recur when switching to a new GLP-1, even if you tolerated your previous medication well
Talk to your doctor before making any changes. They'll help you weigh the convenience benefits of switching against your current progress.
Safety Profile
What Are Foundayo Side Effects?
Like all GLP-1 medications, the most common side effects are gastrointestinal. Most occur during the initial weeks of treatment and improve over time.[3]
Common Side Effects (ATTAIN-1 Trial Data)
Note: Trial used investigational doses (6mg/12mg/36mg). Commercial doses differ but side effect profile is expected to be similar.
| Side Effect | Low Dose | Mid Dose | High Dose | Placebo |
|---|---|---|---|---|
| Nausea | 28.9% | 35.9% | 33.7% | 10.4% |
| Vomiting | 13.0% | 21.4% | 24.0% | 3.5% |
| Diarrhea | 21.0% | 22.8% | 23.1% | 9.6% |
| Constipation | 21.7% | 29.8% | 25.4% | 9.3% |
| Discontinued due to AEs | 5.3% | 7.9% | 10.3% | 2.7% |
Good News: No Food Restrictions Help
Unlike oral Wegovy (which requires strict fasting), Foundayo has no food timing requirements. You can eat whenever you want, which may help manage nausea by eating small, frequent meals.[1]
When to Contact Your Doctor
Seek medical attention if you experience:
- Severe abdominal pain that won't go away (possible pancreatitis)
- Lump or swelling in neck, hoarseness, trouble swallowing (thyroid warning)
- Signs of allergic reaction (rash, swelling, difficulty breathing)
- Severe nausea/vomiting preventing you from keeping down fluids (risk of dehydration)
Pricing & Savings
How Much Does Foundayo Cost?
Foundayo is significantly more affordable than injectable GLP-1s when paying out of pocket. Here's what you can expect to pay (pricing subject to change):[1]
Savings Card + Commercial Insurance
For eligible patients with commercial insurance. Terms valid through 12/31/2026.
Get Savings Card →LillyDirect (Self-Pay)
Direct from Lilly, includes free home delivery. Higher doses cost more.
Learn More →Medicare GLP-1 Bridge
Live now (July 1, 2026 – December 31, 2027) for Part D enrollees who meet CMS’s eligibility criteria. No one opts in: coverage follows your Part D enrollment.
Which Path Is Right for You?
- Have commercial insurance? → Use the savings card ($25/month)
- On Medicare? → Ask your prescriber about the Medicare GLP-1 Bridge ($50 per monthly fill, if you meet CMS’s criteria), or use LillyDirect
- No insurance / denied? → LillyDirect at $149–$299/month
- Denied but want to fight? → Appeal with our help (65%+ success)
Price Comparison: Foundayo vs Other GLP-1s
| Medication | Monthly Cost (Self-Pay) | Administration |
|---|---|---|
| Foundayo | $149–$299 | Daily pill |
| Zepbound | $299–$449 | Weekly injection |
| Wegovy | $349 | Weekly injection |
| Ozempic | ~$900 | Weekly injection |
Coverage Reality
Does Insurance Cover Foundayo?
New Drug = Coverage Uncertainty
Foundayo was just approved in April 2026. Most insurers haven't announced formal coverage policies yet. Expect similar barriers to other GLP-1 medications initially—prior authorization, BMI requirements, and possible denials.[5]
What You Can Do Now (While Coverage Is Being Established)
Don't wait for a denial—start building your case today:
- Document your weight history — 6+ months of records showing BMI ≥30 (or ≥27 with comorbidities)
- Track failed interventions — Diet programs, exercise plans, previous medications that didn't work
- Get comorbidities on record — Sleep apnea, hypertension, pre-diabetes, joint pain, PCOS
- Ask your doctor now — Request a letter of medical necessity stating why Foundayo specifically is indicated for you
If you're denied: This documentation becomes the foundation of your appeal. We help patients win 65%+ of GLP-1 appeals when properly documented.
What to Expect by Plan Type
Commercial Insurance Variable
Coverage: GLP-1s for weight loss are covered by 43% of firms with 5,000+ workers, and 16% of firms with 200–999 workers (2025)
Likely requirements: Prior authorization, BMI criteria, lifestyle documentation
With savings card: $25/month if covered
Medicare Part D Medicare GLP-1 Bridge
Current status: Foundayo is covered by the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) for $50 per monthly fill, if you meet CMS’s eligibility criteria
Important: Not eligible if you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3), or if your Part D plan paid for a GLP-1 for you at any time in 2026.
Not eligible? LillyDirect self-pay ($149–$299/month)
Medicaid Varies by State
Current status: 13 states (as of January 2026) cover GLP-1s for obesity
Caution: Coverage is volatile—verify with your state
Denied? Don't Give Up.
65%+ of GLP-1 appeals succeed when properly documented. If your insurance denies Foundayo, you have the right to appeal—and we can help.
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get starteddenied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
"I found Honest Care online and was very impressed with the letter... the appeal worked!"
"My Appeal was approved the next day. Thank you Honest Care!"
Action Plan
How to Get Foundayo: Next Steps
Ready to try Foundayo? Here's your step-by-step action plan:
Check Your Eligibility
Foundayo is approved for adults with:
- BMI ≥30 (obesity), OR
- BMI ≥27 with at least one weight-related comorbidity (diabetes, hypertension, high cholesterol, sleep apnea, etc.)
Get a Prescription
Talk to your doctor or use a telehealth provider. Discuss:
- Your weight loss goals
- Why you prefer an oral medication
- Your medical history and current medications
Choose Your Access Path
Fastest option: LillyDirect ($149–$299/month, ships to your door)
With insurance: Submit for prior authorization + use savings card ($25/month)
If Denied: Appeal
Insurance denial isn't the end. 65%+ of appeals succeed with proper documentation.
Your Questions Answered
Frequently Asked Questions
The biggest difference is convenience: Foundayo can be taken any time of day, with or without food—no restrictions. Oral Wegovy requires taking it on an empty stomach with only water, then waiting 30 minutes before eating or drinking anything else.[1]
Efficacy: Oral Wegovy shows slightly higher weight loss (~15%) compared to Foundayo (about 12%).[3] In the ACHIEVE-3 trial, Foundayo performed comparably to lower-dose oral semaglutide (Rybelsus 7mg/14mg)—but note this was not a direct comparison against the higher-dose oral Wegovy (25mg).[6]
Both are daily pills from major manufacturers (Lilly vs Novo Nordisk), with similar pricing structures.
It's early. Foundayo was just FDA-approved on April 1, 2026, so most insurers haven't announced formal coverage policies yet. Expect similar barriers to other GLP-1 medications initially:[1]
- Prior authorization likely required
- BMI criteria (≥30 or ≥27 + comorbidity)
- Lifestyle documentation
- Possible step therapy (try other meds first)
Good news: If your commercial plan covers Foundayo, the Foundayo Savings Card can bring the cost to as little as $25 (up to $100 per fill, $1,000 a year, 10 fills). If it doesn't, the card price is the same as self-pay pricing ($149–$299/month), up to 10 fills.[1]
See our coverage guide for the latest updates.
Like all GLP-1 medications, the most common side effects are gastrointestinal: nausea (29-36%), diarrhea, constipation, and vomiting.[3]
Discontinuation rates: 5-10% of trial participants stopped due to side effects (compared to 2.7% with placebo). Most side effects were mild to moderate and occurred during dose escalation.
No injection-related side effects: Unlike Zepbound or Wegovy injections, there are no injection site reactions with Foundayo.
With commercial insurance that covers Foundayo + Foundayo Savings Card: as little as $25 (up to $100 per fill, $1,000 a year, 10 fills).[1]
Self-pay via LillyDirect: $149–$299/month depending on dose, with free home delivery (the top doses cost more if a refill is late).[1]
Medicare Part D enrollees: $50 per monthly fill through the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027), with conditions.
Patient Assistance (Lilly Cares): Zepbound, Mounjaro and Foundayo are not on Lilly Cares’ medication list, so Lilly Cares is not a route to free Foundayo.
See our cost guide for all savings options.
Yes! This is Foundayo's key advantage. Unlike oral Wegovy (which must be taken in the morning on an empty stomach), Foundayo can be taken:[1]
- Morning, afternoon, or evening
- With or without food
- No water restrictions
- No waiting period before eating
This flexibility makes it much easier to fit into your daily routine and may improve real-world adherence compared to other oral GLP-1s.
No! Unlike injectable GLP-1s (Zepbound, Wegovy, Ozempic), Foundayo is a room-temperature pill. No refrigeration needed, no special storage requirements.[1]
This makes Foundayo ideal for travel or situations where refrigeration is unavailable.
Efficacy: Zepbound delivers more weight loss (~20–22%) compared to Foundayo (about 12%). If maximum weight loss is your priority, injectable Zepbound is more effective.[3]
Convenience: Foundayo wins here—daily pill vs weekly injection, no refrigeration, no needles.
Same manufacturer: Both are made by Eli Lilly, so similar savings programs and patient support.
Who chooses Foundayo? Patients who prefer pills over injections, have needle phobia, travel frequently, or value convenience over maximum efficacy.
Now available! Foundayo launched April 2026:[1]
- April 1, 2026: FDA approval, prescriptions accepted
- April 6, 2026: LillyDirect shipping begins (free home delivery)
- Shortly after: Retail pharmacies and telehealth providers
The fastest way to get Foundayo is through LillyDirect at lillydirect.com.
Explore All Foundayo Resources
In-depth guides about Foundayo coverage, appeals, and costs.
Impressive and successful!
My doctor did not even try to appeal when my GLP-1 medication was originally denied, and the thought of appealing myself was overwhelming. I found Honest Care online and was very impressed with the letter and support...
Appeal approved!
I was denied coverage of my GLP-1 medication due to my company changed their requirements. After going over the appeal letter with my doctor (she was incredibly impressed) we submitted and got approved within...
Honest Care gets results!
My insurance refused prior authorization for my GLP-1, but said I could file an appeal. I received my appeal approval the next day. Thank you Honest Care for helping me get my life back.
Explore Other GLP-1 Medications
Compare coverage, costs, and appeal strategies across GLP-1 medications:
References
- Eli Lilly and Company. "FDA Approves Lilly's Foundayo (orforglipron) for Chronic Weight Management." Press Release, April 1, 2026. Lilly Investor Relations
- MedCentral. "Orforglipron: Mechanism of Action and Non-Peptide Structure." February 2026.
- Wharton S, et al. "Orforglipron for the Treatment of Obesity: ATTAIN-1 Trial Results." New England Journal of Medicine, September 2025. ATTAIN-1 Trial (NCT05869903)
- ATTAIN-2 Trial. "Orforglipron in adults with obesity and type 2 diabetes." The Lancet, Vol. 406, Issue 10522, December 2025 (epub November 20, 2025). ATTAIN-2 Trial (NCT05872620)
- KFF. "2025 Employer Health Benefits Survey." Kaiser Family Foundation, October 2025. KFF Survey
- Rosenstock J, et al. "Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a phase 3 trial." The Lancet, March 21, 2026 (epub February 26, 2026). DOI: 10.1016/S0140-6736(26)00202-3. The Lancet
- Eli Lilly and Company. "Foundayo Savings Programs and Pricing." LillyDirect / Foundayo Support Services, April 2026. foundayo.lilly.com
Reviewed by Honest Care GLP-1 SpecialistsLast updated October 6, 2026 · Key facts verified October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.
Foundayo (orforglipron) is an FDA-approved prescription medication for chronic weight management. Coverage and access may vary based on your insurance plan, location, and individual medical circumstances. Always verify current coverage with your insurance provider and discuss treatment options with your healthcare team.